Its effectiveness, demonstrated in clinical trials, showcases substantial weight loss results that have redefined expectations
This program uses compounded semaglutide or tirzepatide, which are non-branded medications that are not FDA-approved
GLP-1 biology isnt about duration, its about precision
Endocrinology, 112(5), 1613-1617
If I could figure out how GLP-1 reduces heart attacks and strokes, and I knew where that magic was happening, maybe we could make even better, more targeted GLP-1 therapies to produce more effective medicines, Drucker says

Choosing Between Semaglutide and Tirzepatide Based on Eligibility You May Be Better Suited for Semaglutide If You prefer steady progress You have mild metabolic slowdown You experience digestive sensitivity You fall at the lower end of the eligibility BMI range You May Be Better Suited for Tirzepatide If You struggle with strong appetite dysregulation You have significant insulin resistance You previously plateaued on Semaglutide You have a higher BMI or desire more rapid improvement Realistic Expectations for Eligible Patients Once on a therapeutic dose most patients experience Early appetite changes Steady weekly weight loss Improved blood sugar stability Higher energy and better mood Fifteen to thirty percent reduction in baseline weight over time GLP-1s support long term metabolic resetting when monitored properly